Benitec Biopharma Inc. (BNTC) |
| 11 -0.12 (-1.08%) 02-25 16:00 |
| Open: | 11.05 |
| High: | 11.23 |
| Low: | 10.68 |
| Volume: | 80,284 |
| Market Cap: | 289(M) |
| PE Ratio: | -10.19 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 13.11 |
| Resistance 1: | 11.86 |
| Pivot price: | 11.22 |
| Support 1: | 9.85 |
| Support 2: | 8.20 |
| 52w High: | 17.15 |
| 52w Low: | 9.8 |
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
Financials
| EPS | -1.080 |
| Book Value | 5.470 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -22.4 |
| Return on Equity (ttm) | -33.5 |
Company news
Mon, 23 Feb 2026
Benitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference - The Manila Times
Mon, 23 Feb 2026
Durable BB-301 responses in muscular dystrophy to be detailed at MDA 2026 - Stock Titan
Thu, 19 Feb 2026
Benitec Biopharma (BNTC) Stock Analysis: Unpacking A 125% Potential Upside - DirectorsTalk Interviews
Sat, 14 Feb 2026
Hedge funds owners may consider drastic measures as Benitec Biopharma Inc.'s (NASDAQ:BNTC) recent US$60m drop adds to long-term losses - simplywall.st
Thu, 12 Feb 2026
BENITEC BIOPHARMA ($BNTC) Releases Q2 2026 Earnings - Quiver Quantitative
Sat, 31 Jan 2026
Benitec Biopharma: BB-301's Early OPMD Data And Cash Infusion Justify A Bullish Upgrade - Seeking Alpha
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
